We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SignalChem and Merck Collaborate To Evaluate AXL Inhibitor and Keytruda in Advanced NSCLC
Product News

SignalChem and Merck Collaborate To Evaluate AXL Inhibitor and Keytruda in Advanced NSCLC

SignalChem and Merck Collaborate To Evaluate AXL Inhibitor and Keytruda in Advanced NSCLC
Product News

SignalChem and Merck Collaborate To Evaluate AXL Inhibitor and Keytruda in Advanced NSCLC

Credit: kalhh/ Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SignalChem and Merck Collaborate To Evaluate AXL Inhibitor and Keytruda in Advanced NSCLC"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer), plays a key role in cell survival, angiogenesis, metastasis and therapeutic resistance. SLC-391 is a clinical stage small molecule AXL inhibitor with high potency, selectivity and desirable pharmaceutical properties. SLC-391 disrupts cell division, inhibiting tumor growth and causing cancer cells to die.

Based on emerging evidence, a clinical investigation has been initiated to evaluate SLC-391 in combination with KEYTRUDA in the treatment of patients with advanced NSCLC.

SignalChem will conduct the study in multiple cancer centers in the US and Canada to evaluate the clinical outcome of combining SLC-391 and KEYTRUDA. The two companies plan to conduct the SKYLITE trial, a phase 2 study for patients with NSCLC.

The SKYLITE trial is a multi-centre, single arm, open-label, Phase 2 Study of SLC-391 in combination with KEYTRUDA in subjects with NSCLC. Subjects will receive daily doses of SLC-391 orally for 21-day cycles in combination with the commercially approved dose and schedule of KEYTRUDA. The SKYLITE trial will evaluate the safety and efficacy of the combination therapy, and includes the exploration of biomarkers relating to AXL signaling that may correlate with anti-tumor activity.

"We welcome the collaboration with Merck. We consider Merck’s clinical development expertise to be valuable and believe this relationship may contribute to the development of SLC-391 for the treatment of patients with advanced stage lung cancer. These patients experience aggressive tumors that are often difficult to treat. We hope this collaboration with Merck will lead to a new approach that addresses this important unmet need," says Mr. Jun Yan, President, SignalChem Lifesciences. "We look forward to partnering with Merck as we aim to deliver new cancer treatments and advance SLC’s drug discovery platform. We at SLC are working hard to identify new anti-tumor, anti-metastatic, and anti-chemo-resistance therapies that provide meaningful alternatives to existing treatments." 

Advertisement